13D Filing: Baker Bros. Advisors and Erytech Pharma SA (ADR) (ERYP)

Page 2 of 10

Page 2 of 10 – SEC Filing

CUSIP No.  29604W108 Page   2   of   10   Pages
1.

NAMES OF REPORTING PERSONS

Baker Bros. Advisors LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)
¨

(b)
¨

3.

SEC USE ONLY

4.

SOURCE OF FUNDS*

OO

5.

CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

¨

6.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER
OF SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON WITH
7.

SOLE VOTING POWER:

4,898,337 (1)

8.

SHARED VOTING POWER:

0

9.

SOLE DISPOSITIVE POWER:

4,898,337 (1)

10.

SHARED DISPOSITIVE POWER:

0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

4,898,337 (1)

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

¨

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

27.3% (1)(2)

14.

TYPE OF REPORTING PERSON*

IA, PN

(1) Includes 3,090,069 of the Ordinary Shares of ERYTECH
Pharma S.A. (the “Issuer”) reported as beneficially owned that are beneficially owned through American Depositary
Shares (“ADS”). Each ADS represents 1 Ordinary Shares of the Issuer.
(2) Based on 17,119,681 Ordinary Shares that will be outstanding
following the Offering (as defined below) plus 806,104 additional ADS and/ or ordinary shares issued as part of the Underwriters
option (as defined below) according to information published by the Issuer on November 10, 2017 and November 15, 2017.

Follow Erytech Pharma S.a. (NASDAQ:ERYP)














Page 2 of 10